|
08/2010:
emergentec patent covering diagnostics aspects in a major chronic disease area successfully licensed to a US-based diagnostics specialist.
07/2010:
idw reports on our Systems Biology approach
(article)
04/2010:
Research on novel anti-cancer antibody supported by emergentec scientists featured by the Austrian Press Agency
(report)
03/2010:
Powerful start of SysKid: 75 researchers gather at the kick-off meeting.
(german)
See www.syskid.eu for details.
02/2010:
Europe tackles Chronic Kidney Disease with Systems Biology.
Press release.
01/2010:
Johannes Soellner, emergentec's head of target R&D, selected as
Member of the Program Committee for the
'Immunoinformatics and Computational Immunology Workshop (ICIW 2010)' to be
held in conjunction with the ACM International Conference on Bioinformatics
and Computational Biology (ACM-BCB), Niagara Falls, NY, U.S.A. August 2-4, 2010.
12/2009:
Negotiations on the EU FP7 funded project SysKID (Systems Biology towards
novel chronic kidney disease diagnosis and treatment) successfully completed.
This large scale integrating Project with a total project volume of close to EUR 16
million is coordinated by emergentec and involves 25 partners from 15
different countries. Project start is January 2010 with a project runtime of 5 years.
09/2009:
emergentec among the 'Austrian Champions in European Research' as presented by the Austrian Research Promotion Agency
(snapshot).
04/2009:
emergentec and the Medical University of Vienna initiate a collaboration on developing a novel biomarker for optimizing cancer treatment.
02/2009:
emergentec patent covering diagnostics aspects in a major chronic disease area successfully licensed to a US-based diagnostics specialist.
10/2008:
Featured research at the Medical University of Innsbruck on identification of kidney survival genes utilizing emergentec's technologies.
(german).
05/2008:
The large scale integrated European Union project 'predict-IV' starts.
emergentec engages in identifying novel toxicology biomarkers of kidney and liver.
04/2008:
Development succeeds by providing emergentec's technologies for novel bone metabolism disorder diagnostics.
article (german).
03/2008:
The R&D consortium nephronic, established by emergentec and clinical partners, is ranked among the most promising start-up ideas at
the Austrian Best-of-Biotech call.
article (german).
02/2008:
emergentec's cancer antigen screening platform is featured in 'Chemiereport'.
article (german).
01/2008:
emergentec and the Technical University of Vienna start a collaboration toward designing improved 'omics' data analysis routines.
08/2007
The SYNLET
project, focusing on tackling cancer chemoresistance, is featured in the 'Tackling Complexity in Science' brochure of the European Commission.
report.
07/2007:
emergentec together with clinical experts establish the research unit
'nephronic biomedical research' aimed at strengthening our R&D on kidney disease diagnostics and therapy.
07/2007:
emergentec and the Medical University of Vienna start a collaboration on developing a novel endometriosis diagnosis kit.
06/2007:
emergentec biodevelopment is featured in 'Chemiereport'. article (german).
02/2007:
SYNLET - a joint European project scientifically headed by emergentec and aimed at identifying novel strategies for cancer drug development starts.
press release.
12/2006:
Biomedica GmbH (Austria), SYNARC SAS (France) and emergentec collaborate towards identifying novel cardiovascular disease markers in the context
of bone metabolism disorders. press release.
10/2006:
The publication 'Alterations in Gene Expression in Cadaveric vs. Live Donor Kidneys Suggest Impaired Tubular Counterbalance of Oxidative Stress at
Implantation', co-authored by members of emergentec, was awarded the 'Austrotransplant-Preis 2006' of the 'Austrian Society of Transplantation,
Transfusion and Genetics'.
05/2006:
emergentec proudly supports the symposium 'Algorithms of Life', Lentos Art Museum Linz, Austria.
05/2006:
emergentec and Green Hills Biotechnology (Vienna, Austria) start a collaborative development of a therapeutic cancer antibody.
04/2006:
emergentec is part of the largest EU funded cancer research diagnostics project initiated in 2006 - OVCAD.
press release.
12/2005:
Technologies of emergentec featured in '100 Technology Offers stemming from EU Biotechnology RTD results', published by the European Commission.
report.
12/2005:
emergentec receives financial support from the Vienna Business Agency to further strengthen translational research efforts.
10/2005:
Partnering wins: Biomedica GmbH, emergentec, and Prof. Marc (University of Ljubljana) win the CoOperate enlarged call 2005.
press release.
02/2005:
emergentec and Green Hills Biotechnology GmbH (Vienna, Austria) start joint development of a cancer diagnostics assay.
12/2004:
emergentec business analytics is renamed to emergentec biodevelopment, reflecting emergentec's strongly increasing R&D focus.
11/2004:
emergentec joins an Influenza Vaccine Consortium supported by EU grants.
press release.
01/2004:
Partnering wins: Biovertis AG and emergentec among the winners of the City of Vienna WWFF funding call 'CoOperate Vienna 2003'.
press release.
07/2003:
emergentec in the 'Wiener Wirtschaft'. article (german).
05/2003:
From DNA-sequences to vaccines. Some remarks at ORF online.
article (german).
12/2002:
Antigenicity: A key factor for the treatment and prophylaxis of infection and cancer - emergentec's contribution. Wiener Zeitung.
article (german).
11/2002:
Partnering wins: Intercell AG and emergentec among the top three at the City of Vienna WWFF Life Science 2002 funding call.
press release.
11/2002:
Mining of Biological Data. Some remarks at ORF online.
article (german).
03/2002:
Formation of the company: emergentec starts its operations.
|
